Two experimental AstraZeneca drugs show promise in ovarian cancer
May 31, 2014 at 07:00 AM EDT
May 31 (Reuters) - A combination of two drugs developed by AstraZeneca Plc, olaparib and cediranib, was shown in a mid-stage study to nearly double the length of time certain ovarian cancer patients lived without their disease getting worse.